93 related articles for article (PubMed ID: 22993341)
1. A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy.
Endo J; Iihara H; Yamada M; Yanase K; Kamiya F; Ito F; Funaguchi N; Ohno Y; Minatoguchi S; Itoh Y
Anticancer Res; 2012 Sep; 32(9):3939-47. PubMed ID: 22993341
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
Yamada Y; Fujita M; Okuyama K; Takayanagi R; Ozeki T; Yokoyama H; Iga T
Yakugaku Zasshi; 2007 Feb; 127(2):353-7. PubMed ID: 17268155
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Jun; 26(7):1001-8. PubMed ID: 10396331
[TBL] [Abstract][Full Text] [Related]
4. Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
Nakamura H; Yokoyama H; Takayanagi R; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):39-44. PubMed ID: 24470169
[TBL] [Abstract][Full Text] [Related]
5. Absorption characteristics of azasetron from rectal and oral routes in rabbits.
Moriyama Y; Arimori K; Nakano M
Biol Pharm Bull; 1997 Jun; 20(6):701-3. PubMed ID: 9212995
[TBL] [Abstract][Full Text] [Related]
6. Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists.
Ayuhara H; Takayanagi R; Okuyama K; Yoshimoto K; Ozeki T; Yokoyama H; Yamada Y
Int J Clin Oncol; 2009 Dec; 14(6):518-24. PubMed ID: 19967488
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
Okuyama K; Yoshimoto K; Iwase O; Ozeki T; Yamada Y
Yakugaku Zasshi; 2008 Apr; 128(4):649-55. PubMed ID: 18379183
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
9. High affinity binding of azasetron hydrochloride to 5-hydroxytryptamine3 receptors in the small intestine of rats.
Katayama K; Asano K; Haga K; Fukuda T
Jpn J Pharmacol; 1997 Apr; 73(4):357-60. PubMed ID: 9165374
[TBL] [Abstract][Full Text] [Related]
10. Method for individualized evaluation of antiemetic effect induced by 5-HT3 receptor antagonist.
Nakamura H; Yokoyama H; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
Biol Pharm Bull; 2013; 36(5):780-7. PubMed ID: 23459393
[TBL] [Abstract][Full Text] [Related]
11. [A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin].
Tsukuda M; Mochimatsu I; Furukawa M; Kohno H; Kawai S; Enomoto H; Yago T; Matsuda H; Ikema Y; Zhou L
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1959-67. PubMed ID: 7487127
[TBL] [Abstract][Full Text] [Related]
12. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy.
Gurpide A; Sadaba B; Martin-Algarra S; Azanza JR; Lopez-Picazo JM; Campanero MA; Cabello JP; Gil-Aldea I; de la Cruz S; Fernandez Gallego V; Reyna C; Olier Garate C; Blanco-Prieto MJ; Ceballos J; Garcia-Foncillas J; Perez-Gracia JL
Oncologist; 2007 Sep; 12(9):1151-5. PubMed ID: 17914085
[TBL] [Abstract][Full Text] [Related]
13. [A randomized crossover comparison of azasetron alone and azasetron plus dexamethasone for the prevention of nausea and vomiting by chemotherapy including cisplatin].
Fujii M; Kanke M; Arai Y; Kawai S; Enomoto H; Inaba H; Taguchi T; Tsukuda M
Gan To Kagaku Ryoho; 2000 Sep; 27(10):1557-63. PubMed ID: 11016001
[TBL] [Abstract][Full Text] [Related]
14. [Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP].
Kimura E; Niimi S; Watanabe A; Akiyama M; Tanaka T
Gan To Kagaku Ryoho; 1996 Mar; 23(4):477-81. PubMed ID: 8678501
[TBL] [Abstract][Full Text] [Related]
15. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Pinarli FG; Elli M; Dagdemir A; Baysal K; Acar S
Pediatr Blood Cancer; 2006 Oct; 47(5):567-71. PubMed ID: 16317736
[TBL] [Abstract][Full Text] [Related]
16. Formulation and in vitro/in vivo correlation of a drug-in-adhesive transdermal patch containing azasetron.
Sun L; Cun D; Yuan B; Cui H; Xi H; Mu L; Chen Y; Liu C; Wang Z; Fang L
J Pharm Sci; 2012 Dec; 101(12):4540-8. PubMed ID: 22972714
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
[TBL] [Abstract][Full Text] [Related]
18. Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 1998 Oct; 71(1):113-5. PubMed ID: 9784330
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
Yonemura M; Katsumata N; Hashimoto H; Satake S; Kaneko M; Kobayashi Y; Takashima A; Kato Y; Takeuchi M; Fujiwara Y; Yamamoto H; Hojo T
Jpn J Clin Oncol; 2009 Jul; 39(7):443-8. PubMed ID: 19395466
[TBL] [Abstract][Full Text] [Related]
20. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
